FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2009869235> ?p ?o ?g. }

• W2009869235 endingPage "244" @default.
• W2009869235 startingPage "239" @default.
• W2009869235 abstract "Both chemotherapy and tamoxifen are widely used either alone or in combination as adjuvant treatment following mastectomy. Despite the fact that both of them exhibit carcinogenic properties in experimental models, detailed reports on the incidence of new primaries following chemotherapy and/or tamoxifen in patients with early breast cancer are limited.To investigate the incidence of new primaries (including opposite breast tumors and skin cancers) in untreated patients and in patients treated with either tamoxifen or chemotherapy or with both modalities.A total of 1696 patients with early breast cancer, 1286 of whom were treated with either CMF-based adjuvant chemotherapy (n = 410), tamoxifen (n = 656) or with a combination of the two (n = 220) were considered for the present analysis. Patients were operated on between November 1983 and December 1991 and were followed up to June 1994. Detailed information about second malignancies were available for all patients.Overall, 53 new primaries, 19 of them opposite breast tumors, occurred in 53 patients. The actuarial cumulative incidence rates at 5 years were: 3.1% (95% CI: 1.4%-4.8%) in untreated patients; 1.7% (95% CI: 0.0%-3.5%) in tamoxifen-treated patients; 4.2% (95% CI: 1.3%-7.1%) in chemotherapy-treated patients and 2.6% (95% CI: 0.0%-5.2%) in the chemo-tamoxifen group (all groups: P = n.s.; chemotherapy-treated versus tamoxifen-treated: P = 0.01). The corresponding figures, after exclusion of the patients with opposite-breast and skin tumors, were: untreated patients: 2% (95% CI: 0.6%-3.4%); tamoxifen-treated patients: 0.95% (95% CI: 0.0%-2.4%); chemotherapy-treated patients: 2.6% (95% CI: 0.4%-4.8%); chemotherapy plus tamoxifen: 1.65% (95% CI: 0.4%-3.8%); (all groups: P = n.s.; CT versus TAM P = 0.05). Chemotherapy-treated patients showed a risk that was about two-fold that of the one to be expected in the general population. By contrast, a decrease in the total risk was observed in patients treated with tamoxifen. Patients who received chemotherapy and tamoxifen as well as those in the no-treatment group showed a risk which was comparable to that of the general population.Adjuvant chemotherapy appears to increase the risk of second malignancies. By contrast, tamoxifen seems to exert an overall protective effect in this regard, and it also appears to counteract, at least partially, the carcinogenic effect of chemotherapy.While there is plenty of evidence that the benefit achieved by adjuvant chemotherapy considerably exceeds the risk of second malignancies, the indiscriminate use of chemotherapy should be avoided, particularly in patients with a low risk of relapse. Moreover, it seems reasonable to prefer tamoxifen over chemotherapy for patients likely to obtain comparable therapeutic benefit from antiestrogenic treatment." @default.
• W2009869235 created "2016-06-24" @default.
• W2009869235 creator A5001753228 @default.
• W2009869235 creator A5033161714 @default.
• W2009869235 creator A5033798845 @default.
• W2009869235 creator A5070979189 @default.
• W2009869235 date "1996-03-01" @default.
• W2009869235 modified "2023-10-03" @default.
• W2009869235 title "Risk of new primaries after chemotherapy and/or tamoxifen treatment for early breast cancer" @default.
• W2009869235 cites W1810933484 @default.
• W2009869235 cites W1844816815 @default.
• W2009869235 cites W1939846443 @default.
• W2009869235 cites W1971495991 @default.
• W2009869235 cites W1976451305 @default.
• W2009869235 cites W1980530855 @default.
• W2009869235 cites W1985581645 @default.
• W2009869235 cites W2040743837 @default.
• W2009869235 cites W2052268677 @default.
• W2009869235 cites W2061908550 @default.
• W2009869235 cites W206480088 @default.
• W2009869235 cites W2096627534 @default.
• W2009869235 cites W2105365583 @default.
• W2009869235 cites W2149944230 @default.
• W2009869235 cites W2150733077 @default.
• W2009869235 cites W2154377786 @default.
• W2009869235 cites W2155481621 @default.
• W2009869235 cites W2263907628 @default.
• W2009869235 cites W4293241248 @default.
• W2009869235 doi "https://doi.org/10.1093/oxfordjournals.annonc.a010566" @default.
• W2009869235 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/8740786" @default.
• W2009869235 hasPublicationYear "1996" @default.
• W2009869235 type Work @default.
• W2009869235 sameAs 2009869235 @default.
• W2009869235 citedByCount "18" @default.
• W2009869235 countsByYear W20098692352012 @default.
• W2009869235 countsByYear W20098692352016 @default.
• W2009869235 countsByYear W20098692352017 @default.
• W2009869235 countsByYear W20098692352019 @default.
• W2009869235 countsByYear W20098692352023 @default.
• W2009869235 crossrefType "journal-article" @default.
• W2009869235 hasAuthorship W2009869235A5001753228 @default.
• W2009869235 hasAuthorship W2009869235A5033161714 @default.
• W2009869235 hasAuthorship W2009869235A5033798845 @default.
• W2009869235 hasAuthorship W2009869235A5070979189 @default.
• W2009869235 hasBestOaLocation W20098692351 @default.
• W2009869235 hasConcept C120665830 @default.
• W2009869235 hasConcept C121332964 @default.
• W2009869235 hasConcept C121608353 @default.
• W2009869235 hasConcept C126322002 @default.
• W2009869235 hasConcept C143998085 @default.
• W2009869235 hasConcept C2776067312 @default.
• W2009869235 hasConcept C2776694085 @default.
• W2009869235 hasConcept C2777176818 @default.
• W2009869235 hasConcept C2777757722 @default.
• W2009869235 hasConcept C530470458 @default.
• W2009869235 hasConcept C61511704 @default.
• W2009869235 hasConcept C71924100 @default.
• W2009869235 hasConceptScore W2009869235C120665830 @default.
• W2009869235 hasConceptScore W2009869235C121332964 @default.
• W2009869235 hasConceptScore W2009869235C121608353 @default.
• W2009869235 hasConceptScore W2009869235C126322002 @default.
• W2009869235 hasConceptScore W2009869235C143998085 @default.
• W2009869235 hasConceptScore W2009869235C2776067312 @default.
• W2009869235 hasConceptScore W2009869235C2776694085 @default.
• W2009869235 hasConceptScore W2009869235C2777176818 @default.
• W2009869235 hasConceptScore W2009869235C2777757722 @default.
• W2009869235 hasConceptScore W2009869235C530470458 @default.
• W2009869235 hasConceptScore W2009869235C61511704 @default.
• W2009869235 hasConceptScore W2009869235C71924100 @default.
• W2009869235 hasIssue "3" @default.
• W2009869235 hasLocation W20098692351 @default.
• W2009869235 hasLocation W20098692352 @default.
• W2009869235 hasOpenAccess W2009869235 @default.
• W2009869235 hasPrimaryLocation W20098692351 @default.
• W2009869235 hasRelatedWork W1514995717 @default.
• W2009869235 hasRelatedWork W1771722205 @default.
• W2009869235 hasRelatedWork W2009869235 @default.
• W2009869235 hasRelatedWork W2027018118 @default.
• W2009869235 hasRelatedWork W2091599823 @default.
• W2009869235 hasRelatedWork W2161568138 @default.
• W2009869235 hasRelatedWork W2401100240 @default.
• W2009869235 hasRelatedWork W2460391067 @default.
• W2009869235 hasRelatedWork W3026603537 @default.
• W2009869235 hasRelatedWork W2181705735 @default.
• W2009869235 hasVolume "7" @default.
• W2009869235 isParatext "false" @default.
• W2009869235 isRetracted "false" @default.
• W2009869235 magId "2009869235" @default.
• W2009869235 workType "article" @default.